Testing a vaccine to reduce HPV infection and spread in women

Plain-English translation of NCT05334706 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This study tests whether Gardasil-9, a vaccine that protects against nine types of HPV, can reduce how contagious HPV16 and HPV18 are in women who already carry these infections. The vaccine works by training your body to make antibodies that can neutralize the virus at sites where it's active, potentially stopping it from spreading to sexual partners. Researchers will measure whether the medication reduces viral infectivity after one, two, and three doses.

Women who already have HPV16 or HPV18 infections may still transmit the virus to sexual partners. This trial investigates whether vaccinating women who already carry these infections could reduce transmission, which could help protect their partners and prevent further spread of the virus.

Do you qualify?

You likely qualify if…

you are a woman aged 18 or older
you were diagnosed with HPV16 and/or HPV18 within the past 10 months
you do not have cervical lesions that need immediate treatment, or you have mild lesions that can be monitored safely
you are willing to receive three vaccine doses over six months and provide cervical, anal, and oral samples

You likely don't qualify if…

you have a severe allergy to vaccine ingredients, including aluminum or yeast
you have a blood clotting disorder or history of severe allergic reactions requiring medical care
you are pregnant or planning to become pregnant during the study
you have a history of ano-genital cancer or HPV-related head and neck cancer
you need cervical surgery or treatment within the next seven months that could affect the study results

What participation looks like

You will receive three vaccine injections: one at the start, one at two months, and one at six months. Throughout the study, you will have samples collected from your cervix, throat, and anal area at different time points to measure how the vaccine affects the virus. The study will also measure your antibody levels before and after vaccination to confirm the vaccine is working as expected.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Trial locations(1 site)

Spain

Gynaecology Unit, Bellvitge University Hospital (HUB), L'Hospitalet de Llobregat, Catalonia

Key details

Phase

Post-approval monitoring

Sponsor

Miquel Angel Pavon Ribas

Collaborators

Hospital del Mar, Catalan Institute of Health

Enrollment target

~69 participants

Started

September 2022

Primary completion

December 2026

Age range

18 Years and older

Sex

Female only

Last updated on clinicaltrials.gov in February 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Miquel Àngel Pavón Ribas, PhD

Cancer Epidemiology Research Program (PREC), Catalan Institute of Oncology (ICO-Hospitalet)/Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov